Radiation Oncology/Drugs/Concurrent chemo

Concurrent chemo-RT schedules

Section	Site	Chemo	RT	Rationale
CNS	Glioblastoma: adjuvant	Temozolomide 75 mg/m2 daily	46 + 14 = 60 Gy	EORTC 26981
GI	Esophagus: neoadjuvant	Cisplatin 100 mg/m2 D1, D29 + C.I. 5-FU 1000 mg/m2 D1-4, D29-32	45 + 5.4 = 50.4 Gy	CALGB 9781
GI	Gastric: adjuvant	Bolus 5-FU 400 mg/m2 + LV 20 mg/m2 first 4 and last 3 days of RT	45 Gy	INT 0116
GI	Pancreas: adjuvant	C.I. 5-FU 250 mg/m2 daily	45 + 5.4 = 50.4 Gy	NCCN
GI	Rectum: neoadjuvant	C.I. 5-FU 225 mg/m2 daily	45 + 5.4 = 50.4 Gy	NCCN
GI	Rectum: adjuvant	C.I. 5-FU 225 mg/m2 daily	45 + 9.0 = 54 Gy	NCCN
GI	Anal: definitive	C.I. 5-FU 1000 mg/m2 D1-4, D29-32; mitomycin 10 mg/m2 D1 and D29	30.6 + 14.4 +/- 5.4-15 Gy = 45-59 Gy	RTOG 98-11
GU	Prostate: definitive	Lupron 7.5 mg IM every month and flutamide 250 mg TID	70 (to 80) Gy	Harvard
GYN	Cervix: adjuvant	Cisplatin 70 mg/m2 and C.I. 5-FU 1000 mg/m2 Q3W	49.3 Gy	GOG 109
GYN	Cervix: definitive	Cisplatin 40 mg/m2 weekly	80-85 Gy Point A	GOG 120
H&N	Head & Neck: adjuvant	Cisplatin 100 mg/m2 Q3W	60-66 Gy	RTOG 95-01
Peds	Medulloblastoma: adjuvant	Vincristine 1.5 mg/m2 weekly	55. 8 Gy	CCG A9961
Thorax	NSCLC: neoadjuvant	Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33	45 Gy	INT-0139
Thorax	NSCLC: definitive	Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33	66 Gy	NCCN
Thorax	SCLC: definitive	Cisplatin 60 mg/m2 D1 and etoposide 120 mg/m2 D1-3 Q3W	45 Gy BID	INT-0096